Elsevier Announces New Journal Partnership
Exciting developments for immunological methods journal
Amsterdam, August 13, 2008 – Elsevier, world-leading publisher of scientific, technical and medical information products and services is pleased to announce that from the beginning of 2008 the respected Journal of Immunological Methods, has become the Official Journal of the Association of Medical Laboratory Immunologists (AMLI).
Launched in 1971, the Journal of Immunological Methods has become a substantial and respected forum in the field of immunology and beyond. The journal received over 10.000 citations in 2007 and is rather unique with a cited-half life of >10 years. Landmark publications, which are still heavily used today, include; “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” (Mosmann, 1983) and “Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability” (Romani et al., 1996).
The partnership with the AMLI is a logical and natural fit bringing benefits to both parties. The organization's mission is to improve the practice of clinical immunology laboratory testing by encouraging education and training of all individuals in the organization, maximizing the quality of test procedures, promoting the exchange of information, supporting clinical research efforts, and improving patient care.
“We consider this an exciting opportunity for the society. All the members will have full text online access to the Journal of Immunological Methods, including its 38-year archive, and we look very much forward to a fruitful collaboration", said Ron Harbeck, current President of AMLI. Editor-in-Chief Michel Nussenzweig commented “The affiliation between the Journal of Immunological Methods and AMLI is an important next step in the life cycle of the journal. Currently, immunological methods are heavily used, both in academic research, as well as in medical and diagnostic laboratories and this will be reflected in this essential publication”.
This year also marks a change in the editorial structure of the journal where, after 24 years, Co-Editor-in-Chief Mac Turner has retired from the journal and Maurice (Mo) O’Gorman, Professor of Pediatrics and Pathology, Northwestern University Medical School, Chicago USA, has been appointed as Reviews and Special Issues Editor.
Floris de Hon, Journal Publisher at Elsevier added: “With this new editorial structure and exciting new relationship with AMLI in place, the Journal of Immunological Methods is now better equipped to respond to the changing needs of the broader community it serves, both in terms of efficiency and relevance”.
The Association of Medical Laboratory Immunologists was organized in 1987 to bring together professional and technical people engaged in the practice and study of medical laboratory immunology. The organization consists of clinical scientists, physicians, dentists, veterinarians, medical technologists, and other professionals engaged in all areas of current laboratory testing. A major focus of the AMLI is to convene an annual meeting exploring various aspects of immunology and medical laboratory immunology.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Floris de Hon
+31 (0) 20 485 2498